Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15806908 | 0.90 | ACHE (0.47) | ACHECHRM5ADRA2CEHMT2OPRK1 | |
| SCHEMBL31010039 | 0.84 | CHRM5 (0.59) | ACHECHRM5ADRA2CEHMT2SMN1; SMN2 | |
| SCHEMBL23205549 | 0.82 | NCF1 (0.42) | ACHECHRM5ADRA2CEHMT2OPRM1 | |
| SCHEMBL22565042 | 0.82 | NCF1 (0.42) | ACHECHRM5ADRA2CEHMT2OPRM1 | |
| SCHEMBL26705172 | 0.82 | ACHE (0.41) | ACHECHRM5ADRA2CEHMT2SMN1; SMN2 | |
| SCHEMBL24414411 | 0.81 | ACHE (0.40) | ACHECHRM5ADRA2CEHMT2KDM4E | |
| SCHEMBL23983526 | 0.81 | ACHE (0.40) | ACHECHRM5ADRA2CEHMT2 | |
| SCHEMBL27097487 | 0.81 | CYP1A2 (0.42) | ACHECHRM5ADRA2CALDH1A1 | |
| SCHEMBL24267386 | 0.80 | ACHE (0.41) | ACHECHRM5ADRA2CEHMT2SMN1; SMN2 | |
| SCHEMBL27097468 | 0.80 | CHRM5 (0.59) | ACHECHRM5ADRA2CSMN1; SMN2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | ACHE 3025/4885CHRM5 4367/4885ADRA2C 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.